---
title: "Survival models"
subtitle: "Part 1"
format: pdf
---


## Clinical question

For patients in the **veteran** lung cancer trial, we want to describe and compare **time-to-death** between treatment arms, and quantify associations with prognostic factors.

Survival data are characterized by:

* a time variable $T$ (follow-up time)

* an event indicator $\delta$ (1 = event occurred, 0 = censored)

We analyze:

$$
{(T_i,\delta_i,X_i)}_{i=1}^n
$$



## Key Quantities

**Survival function**

$$
S(t) = P(T>t)
$$

**Hazard function**

$$
h(t)=\lim_{\Delta t\to 0}\frac{P(t\le T < t+\Delta t \mid T\ge t)}{\Delta t}
$$

Relationship:

$$
S(t)=\exp\left(-\int_0^t h(u),du\right)
$$



## Kaplan–Meier (KM) estimator

Nonparametric estimator of $S(t)$:

$$
\hat S(t) = \prod_{t_j \le t}\left(1-\frac{d_j}{n_j}\right)
$$

where $d_j$ = events at time $t_j$, $n_j$ = at risk just before $t_j$.

KM gives *absolute survival probabilities* over time.


## Log-rank Test (Group Comparison)

Tests:

$$
H_0: S_1(t)=S_2(t)\ \ \forall t
$$

It compares observed vs expected events under $H_0$ across time points (most powerful when hazards are proportional).


## Cox Proportional Hazards model

Models the hazard:

$$
h(t\mid X)=h_0(t)\exp(\beta^\top X)
$$

Key interpretation:

$$
HR_j = e^{\beta_j}
$$

= multiplicative change in hazard for a 1-unit increase in $X_j$, holding others fixed.


## Proportional Hazards (PH) Assumption

Cox assumes *hazard ratios are constant over time*:

$$
\frac{h(t\mid X_1)}{h(t\mid X_2)}=\exp(\beta^\top (X_1-X_2)) \ \text{does not depend on } t
$$

Checked using **Schoenfeld residuals** (e.g., `cox.zph`).


## Parametric Models (Royston–Parmar) as an alternative to Cox PH

Cox is great for **HRs**, but clinical decisions often need **absolute risk**:

* (P(T \le t)) at a horizon (e.g., 180 days)
* RMST up to (\tau)

Flexible parametric models (e.g., spline-based) can produce smooth survival predictions for absolute measures.


## RMST (Restricted Mean Survival Time)

$$
RMST(\tau)=\int_0^\tau S(t),dt
$$



It’s the **average survival time** up to horizon $\tau$.


Treatment effect:
$$
\Delta RMST(\tau)=RMST_{Test}(\tau)-RMST_{Standard}(\tau)
$$

Often easier to interpret clinically than HR.



## Questions 

1. Load packages, inspect data.

```{r}
#| echo: false
library(survival)
library(survminer)
library(dplyr)
library(ggplot2)
library(rstpm2)

data(veteran)

head(veteran)
str(veteran)

# Teaching note:
# In survival::veteran, status is already coded as 1=censored, 2=dead in some versions.
# Many workflows require 0/1 with 1=event, so always confirm coding with table(status).
table(veteran$status)
```


2. Estimate and plot the overall Kaplan–Meier curve.

```{r}

```

Interpretation prompts:

* Median survival time?
* Shape: steep early drop vs gradual decline?


3. Plot KM curves by treatment and compare visually.

```{r}

```

Ask students:

* Do curves separate early or late?
* Do they cross (possible PH concerns)?

3. Log-rank test.

Test:

$$
H_0:S_1(t)=S_2(t)
$$

```{r}
```

Interpretation:

* Small p-value → evidence survival differs between groups.


4. Cox model (multivariable)

$$
h(t\mid X)=h_0(t)\exp(\beta^\top X)
$$

```{r}

```

Interpretation prompts:

* HR(trt): benefit if HR < 1

* karno: expected protective if HR < 1 per higher score


5. Check proportional hazards (PH)

Schoenfeld residual test:

* global test

* variable-specific tests

* plots vs time (trend suggests PH violation)

```{r}

```


7. Fit RP (Royston–Parmar)model and compute 180-day absolute risk

Idea: estimate $S(t\mid X)$ smoothly, then compute:

$$
Risk(t)=1-S(t)
$$

```{r}

```


8. Build predicted survival matrix $S(t)$

```{r, eval=FALSE}
t <- seq(1, max(veteran$time), by = 1)

nd_std  <- transform(newdata, trt = 1, time = t)
nd_test <- transform(newdata, trt = 2, time = t)

S_std  <- as.numeric(predict(rp_model, type = "surv", newdata = nd_std))
S_test <- as.numeric(predict(rp_model, type = "surv", newdata = nd_test))

S <- cbind(Standard = S_std, Test = S_test)
```


9. RMST helpers

$$
RMST(\tau)=\int_0^\tau S(t),dt
$$

```{r, eval=FALSE}
rmst_from_survmat <- function(t, S, tau) {
  stopifnot(is.numeric(t), is.matrix(S), length(t) == nrow(S))
  ord <- order(t)
  t <- t[ord]
  S <- S[ord, , drop = FALSE]

  keep <- t <= tau
  t0 <- t[keep]
  S0 <- S[keep, , drop = FALSE]

  if (length(t0) == 0) return(rep(tau, ncol(S)))

  if (max(t0) < tau) {
    t0 <- c(t0, tau)
    S0 <- rbind(S0, S0[nrow(S0), , drop = FALSE])
  }

  dt <- diff(t0)
  S_left  <- S0[-nrow(S0), , drop = FALSE]
  S_right <- S0[-1, , drop = FALSE]
  colSums((S_left + S_right) / 2 * dt)
}

rmst_curve_from_survmat <- function(t, S) {
  stopifnot(is.numeric(t), is.matrix(S), length(t) == nrow(S))
  ord <- order(t)
  t <- t[ord]
  S <- S[ord, , drop = FALSE]

  dt <- diff(t)
  S_left  <- S[-nrow(S), , drop = FALSE]
  S_right <- S[-1, , drop = FALSE]

  incr <- (S_left + S_right) / 2 * dt
  rmst <- apply(incr, 2, cumsum)

  out <- data.frame(tau = t[-1], rmst)
  names(out)[-1] <- colnames(S)
  out
}
```


10. RMST at $\tau = 180$ days

```{r}

```


11. $RMST(\tau)$ curves and $\Delta RMST(\tau)$

```{r, eval=FALSE}
library(tidyr)
library(ggplot2)

rmst_curve <- rmst_curve_from_survmat(t, S)

rmst_long <- rmst_curve |>
  pivot_longer(-tau, names_to = "arm", values_to = "rmst")

ggplot(rmst_long, aes(tau, rmst, color = arm)) +
  geom_line(linewidth = 1.1) +
  labs(
    title = "Model-based RMST(τ) curves (RP predicted survival)",
    x = "τ (days)",
    y = "RMST(τ)"
  ) +
  theme_minimal()

rmst_delta <- rmst_curve |>
  mutate(delta = Test - Standard)

ggplot(rmst_delta, aes(tau, delta)) +
  geom_hline(yintercept = 0, linetype = 2) +
  geom_line(linewidth = 1.1) +
  labs(
    title = "ΔRMST(τ) = RMST_Test(τ) − RMST_Standard(τ)",
    x = "τ (days)",
    y = "ΔRMST(τ)"
  ) +
  theme_minimal()
```


12. Final clinical questions: 

- Does treatment improve survival (KM / log-rank / Cox HR)?

- Any PH violation (`cox.zph`)?

- Which is clearer clinically: HR (Cox) or absolute risk at 180 days (RP)?

- From $\Delta RMST(\tau)$, for which horizons does treatment provide meaningful gain?
